Introduction {#s1}
============

Neuropeptide Y (NPY), a 36--amino acid peptide member of the pancreatic polypeptide family, is abundant in brain regions, including the amygdala and hippocampus, as a peptide neurotransmitter ([@CIT0013]).

NPY is associated with stress response and regulation. Low brain NPY levels are reported in pre-clinical models ([@CIT0018], [@CIT0017]), including animal models of posttraumatic stress disorder (PTSD; [@CIT0007]), and some clinical studies of cerebrospinal fluid (CSF) NPY in depression and anxiety ([Table 1](#T1){ref-type="table"}). Conversely, studies find higher NPY brain levels---most consistently in the prefrontal cortex---in response to antidepressants and associated with resilience against stress ([@CIT0032]). However, findings concerning the CSF NPY levels and clinical factors are inconsistent across studies. Because CSF and plasma NPY are weakly correlated ([@CIT0500]), we have focused our summary in [Table 1](#T1){ref-type="table"} on CSF studies.

###### 

Summary of Clinical Studies Measuring CSF NPY-LI.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Subjects                                                       Methods (Samples, Techniques)                                                   Results
  ----------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Berrettini et al., 1987       MDD and bipolar, drug free: n = 38\                            CSF (NPY-LI) at baseline\                                                       CSF NPY-LI:\
                                Chronic schizophrenia, drug free: n = 20\                      Schizophrenics had\                                                             MDD = Medicated schizophrenia =Drug free schizophrenia = healthy volunteers
                                Chronic schizophrenia, medicated: n = 15\                      repeated CSF after 1 month of randomized fluphenazine (24mg/d) tx\              
                                Healthy volunteers: n = 33                                     High pressure liquid chromatography                                             

  [@CIT0502]                    MDD, baseline, drug free: n = 33 /\                            CSF (NPY-LI) at baseline and after tx\                                          CSF NPY-LI:\
                                post tx (TCA. MAOI): n = 10\                                   RIA                                                                             MDD\<healthy volunteers or Schizophrenia\
                                Schizophrenia,baseline, drug free: n = 35 / post tx: n = 16\                                                                                   No effect of tx in depression or schizophrenia
                                Healthy volunteers: n = 22                                                                                                                     

  Traskman-Bendz et al., 1992   Suicide attempters,\                                           CSF (NPY-LI)\                                                                   CSF NPY-LI:\
                                drug free:\                                                    RIA                                                                             MDD = Non-MDD
                                MDD: n=16\                                                                                                                                     
                                Non-MDD: n=28                                                                                                                                  

  Heilig, 2004                  MDD- TRD, drug free:\                                          CSF (NPY-LI)\                                                                   CSF NPY-LI:\
                                n = 51\                                                        Competitive\                                                                    MDD-TRD \< healthy volunteers
                                Healthy volunteers: n = 27                                     RIA                                                                             

  Nikisch et al., 2005          MDD, hospitalized, drug free: n = 21                           CSF (NPY-LI) at baseline and after 4 w citalopram tx\                           CSF NPY-LI:\
                                                                                               RIA                                                                             Citalopramtx→↑NPY-LI and ↓CRH-LI

  Hou et al., 2006              MDD-severe, drug\                                              CSF (NPY-LI)\                                                                   CSF NPY-LI:\
                                free: n = 40\                                                  ELISA                                                                           MDD=healthy volunteers\
                                Healthy volunteers: n = 40                                                                                                                     1^st^ episode MDD \< recurrent MDD

  Nikisch and Mathe, 2008       MDD-TRD, drug free: n = 6                                      CSF (NPY- LI) at baseline and after 6 ECT tx\                                   CSF NPY-LI:\
                                                                                               RIA                                                                             ECT- tx→ ↑NPY-LI and ↓ CRH-LI

  [@CIT0501]                    Chronic PTSD, Males, drug free:\                               CSF (NPY- LI)\                                                                  CSF NPY-LI:\
                                n = 10\                                                        Competitive RIA                                                                 PTSD \< healthy volunteers
                                Healthy volunteers, Male: n = 13                                                                                                               

  Martinez et al., 2012         MDD-moderate, drug free:\                                      CSF (NPY-LI) at baseline and after 8 w tx\                                      Baseline CSF NPY:\
                                n = 18\                                                        ELISA                                                                           MDD \> healthy volunteers\
                                Healthy volunteers: n = 25                                                                                                                     No effect of tx on NPY-LI

  Nikisch et al., 2012          Schizophrenia: n = 22                                          CSF (NPY-LI and CRH-LI) at baseline and after 4 w quetiapine tx (600mg/d) RIA   Quetiapine→ ↑NPY- LI and ↓CRH-LI and strongly correlated to the decrease in depression and anxiety PANSS items
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRH-LI, CRH-like immunoreactivity; d, day; ECT, electroconvulsive therapy; ELISA, enzyme-linked immunosorbent assay; MAOI, monoamine oxidase inhibitors; PANSS, positive and negative syndrome scale; RIA, radioimmunoassay; TCA, tricyclic antidepressants; TRD, treatment resistant depression; Tx, treatment; W, week.

Risk of major depression in adulthood is affected by genetic factors ([@CIT0008]), childhood adversity ([@CIT0031]), and their interaction ([@CIT0006]). Many studies of NPY in major depression do not consider the potential role of childhood trauma on NPY levels (see [Table 1](#T1){ref-type="table"} for review). Since major depression itself can be a severe stressor, NPY levels could either be increased as a result of a homeostatic response or have low levels, conferring lower resilience and increasing the risk of depression in the face of later adulthood stress.

The objective of this study was to test these two alternative models and identify the predominant model by examining CSF NPY--like immunoreactivity (NPY-LI) levels in drug-free, currently-depressed subjects with a major depressive disorder as compared to healthy volunteers, and to investigate the effect of reported childhood trauma on CSF NPY-LI in the major depressive disorder (MDD) group.

Materials and methods {#s2}
=====================

Subjects {#s3}
--------

Depressed subjects and healthy volunteers aging 18--70 yrs were recruited through advertising and referrals and admitted to a university hospital for participation in this mood disorders research. All subjects gave written informed consent as required by the Institutional Review Board. DSM-IV Axis I and Axis II disorders were diagnosed based on the structured clinical interview for DSM Axis I ([@CIT0011]); and the structured clinical interview for DSM Axis II ([@CIT0010]);, respectively. Healthy volunteers were free of psychiatric disorder based on the structured clinical interview for DSM non-patient version. Healthy volunteers were medication-free, had no psychiatric history based on the non-patient version of the structured clinical interview for DSM Axis I, were medically free from significant illness, and had no history of a mood or psychotic disorder in any of their first-degree relatives. All depressed subjects met DSM-IV criteria for a current major depressive episode, were free from active medical illness, and were medication-free for at least two weeks period prior to the lumbar puncture (four weeks in the case of neuroleptics and six weeks for fluoxetine). Patients with bipolar or schizophrenia spectrum disorders or those with a family history of schizophrenia or schizoaffective disorder were excluded from the study.

All subjects had a physical examination and routine laboratory tests, including a toxicological screen at baseline to rule out neurological or medical illness or illicit drugs that could affect their mental status or CSF indices.

Current severity of depression was assessed by the Hamilton Depression Rating Scale 17-item version (HDRS-17; [@CIT0012]) that was amended to permit rating of reversed vegetative signs. A history of childhood physical or sexual abuse prior to the age of 15 was determined by specific screening questions, but duration or severity of abuse was not quantified.

Cerebrospinal Fluid Collection and Assay {#s4}
----------------------------------------

On the night before the procedure, subjects had nothing but water after midnight and remained in bed from that time until the lumbar puncture was performed at about 8:00 AM. Cerebrospinal fluid was withdrawn from the L4--L5 interspace, with the subject in the left decubitus position. After the removal of 1mL of CSF into the first sample tube, a further 15mL of CSF was collected in the second and third tubes. These tubes were then immediately transferred onto ice water, centrifuged at 4°C, and the supernatant was pooled from the second and third tubes. The 15mL of supernatant was divided into 1mL aliquots for storage at -70 °C until assay. NPY-LI was assayed in duplicate in one of the 1mL aliquots of the 15mL sample by the radioimmunoassay as previously described ([@CIT0021]). The lower level of sensitivity of the assay was 1.2 pmol/L. Intra- and inter-assay coefficients of variation were 4 and 8%, respectively. Samples were run in duplicate, the mean of which was used for statistical analyses.

Data Analysis {#s5}
-------------

Diagnostic groups (MDD and healthy volunteer groups) and MDD subgroups (reported childhood abuse history versus no abuse) were characterized with respect to clinical and demographic factors. The primary outcome measure of the study was CSF NPY- LI level. The normal distribution of age, CSF concentration of NPY-LI, and HDRS-17 scores were tested by the Kolmogorov-Smirnov test. Normality in CSF NYP-LI data was achieved by square root transformation (tNPY-LI = Sqrt NPY-LI). Means are reported as value ± standard deviation. Group differences for all continuous measures were calculated by either a student's t-test or Mann--Whitney U Test. Correlation analyses were calculated using Pearson's coefficient. ANCOVA compared tNPY-LI across groups with age as a covariate. The *p* values are two-tailed unless otherwise specified. Statistical analyses were performed using IBM Statistics v.20 (SPSS, Inc., 2011) for Mac.

Results {#s6}
=======

Sample Characteristics {#s7}
----------------------

There were 81 participants enrolled in the study, including 20 healthy volunteers (mean age 34 yrs) and 61 patients with a DSM-IV diagnosis of MDD (25 MDD abuse with mean age 41 yrs and 36 MDD abuse with mean age 38 yrs, assigned based on reported childhood physical or sexual abuse). One subject was omitted from the abuse subtype analysis because information about the type of abuse was missing. There were no differences between depressed and healthy groups in terms of sex, age, and ethnicity. The HDRS-17 score was 19.6±5.5, indicating a moderate level of severity of depression.

Associations Between CSF NPY-LI Levels, MDD, and Reported Childhood Abuse {#s8}
-------------------------------------------------------------------------

The MDD group had higher tNPY-LI level (7.9±1.5 pmol/L) compared with healthy volunteers (7.0±1.3 pmol/L, t~79~ = -2.64, *p* = 0.01), which remained significant when controlling for effect of age on NPY-LI (F~1,78~ = 7.91, *p* = 0.03). Depression severity (HDRS-17) showed a modest positive correlation with tNPY-LI (r = 0.22, *p* = 0.04). However, there were no correlations between CSF tNPY-LI and age of MDD onset (*p* = 0.79) or number of episodes (*p* = 0.43). Positive family history (at least one family member with depression) was associated with higher HDRS-17 scores (positive family history, 19.4±6.0; no family history, 12.0±10.3; t~78~ = -3.75; *p* \< 0.0001) and higher CSF tNPY-LI (positive family history, 8.1±1.0 pmol/L; no family history, 7.4±1.6 pmol/L; t~78~ = -2.48; *p* = 0.015).

Neither the presence nor the absence of childhood abuse affected CSF tNPY-LI levels (*p* = 0.32). However, in considering trauma subgroups, it was observed that MDD participants who reported both childhood physical and sexual abuse had higher CSF tNPY-LI compared with healthy volunteers (*p* \< 0.0001), MDD participants who were not abused (*p* = 0.02), and MDD participants reporting physical abuse alone (*p* = 0.02, [Figure 1](#F1){ref-type="fig"}), even after controlling for age (F~4,74~ = 3.82, *p* = 0.007).

![Transformed cerebrospinal fluid neuropeptide Y (tNPY-LI = Sqrt NPY-LI) and subtypes of childhood abuse in major depressive disorder (MDD) compared with healthy volunteers (\**p* \< 0.05, \*\**p* \< 0.0001).](ijnppy_pyu023_f0001){#F1}

The rate of PTSD was higher in participants with history of abuse (29%) compared to those with no history (4.2%, C^2^(69) = 11.22, *p* = 0.004). In those with childhood abuse, tNPY-LI levels were not different between subjects who developed PTSD compared to those who did not. However, the PTSD group did show a trend for higher CSF tNPY-LI levels compared to those without PTSD (non-PTSD, 7.6±1.2 pmol/L; PTSD, 9.0±1.9 pmol/L; *p* = 0.062).

Given that weight and food intake may be related to NPY, we determined that weight did not differ between MDD and healthy volunteer groups or between those MDDs with or without abuse history. Within the MDD and the healthy volunteer groups, weight did not correlate with CSF tNPY-LI levels.

Discussion {#s9}
==========

We found higher CSF NPY-LI levels in medication-free, currently-depressed MDD patients compared with healthy volunteers. Age had a weak positive correlation with CSF NPY-LI level, as previously described ([@CIT0027]), but did not explain the MDD finding. Severity of depression and a positive family history of depression showed modest positive correlations with CSF NPY-LI levels. In terms of effect of childhood adversity history, we found that MDD participants who reported both physical and sexual childhood abuse had higher CSF NPY- LI. Sexual or physical abuse alone in the MDD group was not associated with elevated CSF NPY-LI. Abuse history increased the rate of co-morbid PTSD, and there was a statistical trend for higher CSF NPY-LI with comorbid PTSD. In sum, our findings suggest the predominant picture in MDD is that of higher CSF NPY-LI, it is correlated with depression severity, and both are related to more childhood adversity and co-morbid PTSD.

Animal models of depression, including genetic inbred models (e.g., Flinders Sensitive Line rats and Fawn Hooded rats), chronic mild stress models, the olfactory bulbectomized rat model, and maternal separation (reviewed in [@CIT0013]) have low NPY, indicating it is a biological correlate of such trait depression--like behaviors. Animal models of trait depression differ from the episodic illness course most common in MDD and our patient sample, and may have a different pathophysiology. Some animal models of depression have lower tryptophan hydroxylase levels and lower brain serotonin, whereas human MDD is characterized by over-expression of this enzyme and more serotonin in the brainstem ([@CIT0001]). Perhaps the NPY findings in rodent depression models also do not apply to MDD. Conversely, antidepressant drugs, lithium, or electroconvulsive stimuli increase NPY-LI and NPY mRNA expression in discrete brain regions ([@CIT0014]; [@CIT0032]).

The clinical studies of CSF NPY in MDD are not in agreement. Some clinical studies are consistent with our findings ([@CIT0003]; [@CIT0029]; [@CIT0015]; [@CIT0019]). One patient study did not find CSF NPY-LI differences between MDD and non-MDD ([@CIT0029]); neither did a postmortem study of major depression and NPY-LI ([@CIT0024]).

A comparison of 40 severely-depressed, drug-free subjects with 40 healthy volunteers found no group differences but reported a higher level of NPY-LI in recurrent MDD compared with the first episode of MDD, and concluded that higher CSF NPY-LI could be indicative of adaptation to multiple depressive episodes. Our study population mostly had multiple episodes of major depression. Higher NPY-LI was also found in 18 MDD patients compared with 25 healthy subjects ([@CIT0019]). Thus, these two studies support our findings of higher CSF NPY-LI in major depression.

Other studies ([Table 1](#T1){ref-type="table"}) reported low CSF or plasma NPY-LI levels in depression ([@CIT0013]; [@CIT0021], [@CIT0022]; [@CIT0023]) and in bipolar disorder ([@CIT0005]).

Antidepressant treatments, such as citalopram or electroconvulsive therapy, increase CSF NPY-LI levels in major depression ([@CIT0021], [@CIT0022]; [@CIT0023]) and clinical improvement correlates with the increase in CSF NPY-LI level.

NPY may be altered as a result of childhood adversity, analogous to the stress response recalibration reported for the hypothalamic pituitary adrenal axis and the noradrenergic system. CRH receptor mRNA and NPY Y1 and Y2 receptor mRNA are expressed throughout the amygdala ([@CIT0013]), where stressful sensory inputs are integrated leading to an initiation of the stress response. Rapid activation of CRH in the central nucleus of the amygdala during the initial phase of stress response is followed by a slower activation of NPY, perhaps in order to oppose the maladaptive consequences of excessive or prolonged CRH activation. Maintaining a balance between the CRH and NPY systems might be critical for a normal physiological function and psychological state and for avoiding psychopathology (summarized in [@CIT0030]). An anxiolytic effect of NPY has been observed in animal models, such as the elevated plus-maze ([@CIT0004]), social interaction test ([@CIT0009]), light-dark compartment test ([@CIT0025]), and fear-potentiated startle model ([@CIT0004]). Maternal separation in rodents alters adult brain NPY expression, resulting in lower NPY levels in the hippocampus and occipital cortex and higher NPY levels in the hypothalamus; chronic treatment with lithium ameliorates these changes ([@CIT0017]; [@CIT0016]). Chronic stress, raises amygdala NPY mRNA levels as an adaptive response ([@CIT0028]). Human studies have shown increases in plasma NPY in response to acute uncontrollable stress ([@CIT0013]). Higher NPY concentrations are associated with increased resilience and less psychological distress, and combat-related PTSD patients have lower baseline NPY plasma levels compared with healthy non-traumatized subjects ([@CIT0020]).

Higher NPY level might therefore be a compensatory mechanism in some patients and lower levels may indicate an impaired stress response in others, including some who develop PTSD. Our results indicate higher CSF NPY-LI levels in major depression, indicating the NPY-LI related stress response may be intact but insufficient for preventing episodes of major depression. Our finding of a positive correlation of CSF NPY-LI with both severity of depression and a family history of major depression is also consistent with a model proposing that higher CSF NPY-LI levels are a response to the stress of recurrent major depression in a group with familial depression. [Figure 2](#F2){ref-type="fig"} shows a model of adequate resilience response, but we did not study healthy resilient subjects with a past history of childhood adversity to determine if their NPY levels were even higher and thereby accounted for their resilience.

![NPY response in major depression. High NPY levels in depressed patients may be indicative of an insufficiently resilient response to stress.](ijnppy_pyu023_f0002){#F2}

Despite the relationship of NPY to food intake and weight ([@CIT0026]), we found no such relationship in either MDD or healthy volunteers, and weight did not explain our findings.

We did not find a simple effect of the presence or absence of reported childhood abuse on CSF NPY-LI levels. However, we found that the co-occurrence of childhood physical and sexual abuse was associated with higher levels of NPY-LI ([Figure 1](#F1){ref-type="fig"}). Therefore, increased expression of NPY in the brain may reflect a homeostatic response to the exposure of a greater allostatic load of multiple types of early childhood trauma. Thus, there may be different phenocopies of major depression: one that is primarily genetic and has an intact or robust NPY stress response and a second that is primarily a major depression where a less robust NPY response to MDD indicates an impaired NPY stress response ([Figure 2](#F2){ref-type="fig"}). Some studies, such as ours, mainly detected the former subtype of depression, which may involve a recurrent depression with a higher rate of positive family history, consistent with a pathogenic pathway involving genes and environment. Differences in results in the literature could be explained by the composition of the MDD study populations in terms of the proportion of NPY-sufficient and NPY-insufficient resilient response subjects ([Figure 2](#F2){ref-type="fig"}). That may be determined by comparing laboratory stress responses or clinical differences such as in-family history of MDD, early age of onset of MDD, severity of recent stressful life events preceding the onset of an episode of major depression, and perhaps abnormalities in other stress response systems such as the hypothalamic pituitary adrenal axis.

The limitations of the current study involve a limited measure of childhood abuse based on a qualitative measurement of the presence or absence of reported physical and/or sexual trauma prior to the age of 15. Other types of trauma (e.g., neglect) were not accounted for. Using a standard trauma scale such as the Childhood Trauma Questionnaire ([@CIT0002]) could add precision to the measurement of the severity of childhood adversity. Including resilient healthy controls with histories of childhood trauma would further clarify the mechanisms of the adaptive NPY response. An expanded study sample may reveal a bimodal distribution of CSF NPY where the high NPY group has a resilient response and the low NPY group has the vulnerability biological phenotype.
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